• Contact info@abtriva.com for inquiries and orders.
  • Chinese (Simplified)

  • English

  • German

  • Korean

  • Spanish

United States (English / $ USD)

Recombinant Human Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein (PRIC285), Truncated

ACP10716

Number
Order Exclusive Products Now

Request a Quote
High Purity LevelsPrecision and ReliabilityCustomization Options

Specifications


Cat.No ACP10716 Target NameHELZ2
FormLyophilized powderExpression SystemCustom Production. Please inquire and provide the desire expression system.
Protein LengthPartialPurity>85% (SDS-PAGE)
Storage Buffer5%-50% glycerol. Lyophilized powder form: the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, Liquid form: default storage buffer is Tris/PBS-based buffer, pH 8.0.

Immunogen Information


Target SpeciesHumanUniprot IDQ9BYK8
Background Information
  • Uniprot Id

    Q9BYK8

  • Target Species

    Human

  • Target Name

    HELZ2

  • Target Full Name

    3'-5' exoribonuclease HELZ2

  • Target Function

    Helicase that acts as a transcriptional coactivator for a number of nuclear receptors including PPARA, PPARG, THRA, THRB and RXRA.

  • Target Subcellular Location

    Nucleus.

  • Target Protein Families

    DNA2/NAM7 helicase family

  • Target Tissue Specificity

    Expressed in various tissues including heart, pancreas, skeletal muscle, colon, spleen, liver, kidney, lung, peripheral blood and placenta.

  • Target Synonyms

    ATP-dependent helicase PRIC285; KIAA1769; PDIP1; Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein; PPAR-alpha-interacting complex protein 285; PPAR-gamma DBD-interacting protein 1; PPAR-gamma DNA-binding domain-interacting protein 1; PR285_HUMAN; PRIC285; PRPF8

Inquire Recombinant Human Peroxisomal proliferator-activated receptor A-interacting complex 285 kDa protein (PRIC285), Truncated Now



AbTriva respects your privacy and protects your personal data in accordance with AbTriva. For more information, please see our data protection statement. *

Notification